Vasculitis Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a condition called MPA (microscopic polyangiitis) or GPA (granulomatosis with polyangiitis), regardless of their ANCA blood test result
• People aged 18 years or older
• People whose condition is either newly diagnosed or has come back after a period of remission, and whose disease is currently inactive (confirmed by a disease activity score of zero)
• People who are currently receiving maintenance doses of a medication called rituximab, given at 6 months and 12 months after their initial treatment began
• People who are taking between 5 and 10 mg per day of prednisone (a steroid) at the time of the screening visit, and exactly 5 mg per day at the time of the enrolment visit
• People who are able to provide written consent to take part in the study before it begins

Who may not be able to join:

• People who have a different type of vasculitis (blood vessel inflammation), such as EGPA or others classified under recognised medical classification systems
• People whose vasculitis is currently active (confirmed by a disease activity score above zero)
• People who have an active infection, either current or ongoing, including HIV, hepatitis B, or hepatitis C
• People who currently have cancer, or who have had cancer within the past 5 years — though certain low-risk skin cancers and prostate cancer well-controlled by hormone treatment may be considered (confirm with trial site)
• People who are pregnant or breastfeeding; people who could become pregnant would need to use reliable contraception for the entire duration of the study
• People who have other serious uncontrolled health conditions — including severe mental health conditions or drug or alcohol dependency — that could affect their ability to participate
• People who have taken part in another clinical drug trial within the previous 3 months
• People who are considered unlikely to follow the treatment plan as required by the study
• People whose white blood cell count is at or below 4,000 per mm³
• People whose platelet count is at or below 100,000 per mm³
• People whose liver enzyme levels (ALT or AST) are more than 3 times the accepted normal upper limit, where this cannot be explained by their MPA or GPA condition
• People who are unable to provide written consent to participate
• People for whom rituximab is medically unsuitable or contraindicated

Important: Always verify eligibility with the trial site directly before applying.